Bathla Group Hires Administrators as Australia Housing Slump Deepens 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Nvidia Options Price in $280 Billion Earnings Swing 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Trump Buys SpaceX Shares After Record IPO 
Add as a preferred source on Google
REDWOOD CITY, Calif., April 19, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective April 19, 2018, the compensation committee of the company’s board of directors granted 9 new employees options to purchase an aggregate of 187,000 shares of the company’s common stock with a per share exercise price of $12.05, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
